Topoisomerase Inhibitors and Targeted Delivery in Cancer Therapy

Curr Top Med Chem. 2019;19(9):713-729. doi: 10.2174/1568026619666190401112948.

Abstract

DNA topoisomerases are enzymes that catalyze the alteration of DNA topology with transiently induced DNA strand breakage, essential for DNA replication. Topoisomerases are validated cancer chemotherapy targets. Anticancer agents targeting Topoisomerase I and II have been in clinical use and proven to be highly effective, though with significant side effects. There are tremendous efforts to develop new generation of topoisomerase inhibitors. Targeted delivery of topoisomerase inhibitors is another way to reduce the side effects. Conjugates of topoisomerases inhibitors with antibody, polymer, or small molecule are developed to target these inhibitors to tumor sites.

Keywords: Cancer target; DNA strain break; Targeted delivery; Topoisomerase; Topoisomerase inhibitors; Topology of DNA..

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Cell Proliferation / drug effects
  • DNA Topoisomerases, Type I / metabolism*
  • DNA Topoisomerases, Type II / metabolism*
  • Drug Delivery Systems*
  • Humans
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Topoisomerase Inhibitors / chemical synthesis
  • Topoisomerase Inhibitors / chemistry
  • Topoisomerase Inhibitors / pharmacology*

Substances

  • Antineoplastic Agents
  • Topoisomerase Inhibitors
  • DNA Topoisomerases, Type I
  • DNA Topoisomerases, Type II